A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Amplified|Advanced Breast Cancer|Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions: DRUG: Enzalutamide|DRUG: Trastuzumab
Sponsor: Astellas Pharma Global Development, Inc.
Collaborators: Medivation LLC, a wholly owned subsidiary of Pfizer Inc.